Advertisement

Matching FSGS Therapy to Disease Phase, With Astrid Weins, MD, PhD

Published on: 

Sparsentan, B cell therapies, and TRPC6 and APOL1 inhibitors may each fit a different stage and cause of FSGS.

Getting the most from a growing set of therapies for focal segmental glomerulosclerosis (FSGS) may depend on knowing which phase of disease a patient is in and what is driving it, according to Astrid Weins, MD, PhD, chief of integrated renal pathology at Mass General Brigham, in an interview with HCPLive.

Weins moderated “Advances in Treatment and Management of FSGS,” an educational symposium at American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado.¹ The session reviewed the newest trials and therapies in FSGS. Nephrologists Jai Radhakrishnan, MD, MS, of Columbia University Irving Medical Center, and Vladimir Tesar, MD, PhD, of Charles University in Prague, explained how those findings are shaping their current approach to patients.

Where Sparsentan Fits in FSGS Treatment

In April 2026, the US Food and Drug Administration (FDA) approved sparsentan (Filspari) to reduce proteinuria in patients aged ≥8 years with FSGS without nephrotic syndrome. It was the first approved therapy for the disease.² Sparsentan is a dual endothelin type A and angiotensin II type 1 receptor antagonist.

Weins described sparsentan as a supportive therapy that can help in almost any case of podocyte loss, replacing an ACE inhibitor or angiotensin receptor blocker and adding endothelin blockade.

“It is more a therapy that will generally reduce proteinuria more in patients that have adaptive FSGS or are in the later phase of their disease journey,” she said.

B Cell Directed Therapies for Immune-Mediated Podocytopathy

“What really helps the patients acutely, especially in autoimmune mediated podocytopathies, are B cell directed therapies,” Weins said.

She expects a large group of B cell directed or B cell modulating drugs to be approved over the coming months and years, including APRIL and BAFF inhibitors and CD19 and CD20 inhibitors. In her view, these agents matter most in the early, immunologically active phase of FSGS and diffuse podocytopathies.

Most of these trials are still ongoing. Weins said early results look promising and that lessons from IgA nephropathy (IgAN) are now carrying over to podocytopathies. In the phase 3 TURING trial, the anti-CD20 agent rituximab reduced relapse rates in adults with minimal change disease and FSGS.

TRPC6 Inhibition and APOL1-Targeted Therapy in FSGS

Weins also pointed to TRPC6 inhibition. In a 12-week phase 2 trial in primary FSGS, the oral TRPC6 inhibitor apecotrep reduced proteinuria by 40% compared with placebo at the 20 mg dose, and a phase 3 program is recruiting.³ She sees it as a potential add-on therapy rather than a stand-alone treatment.

She also highlighted therapy targeting APOL1, which she believes could benefit patients of African descent who carry APOL1 high-risk alleles by protecting their podocytes. Vertex has completed enrollment in its phase 2/3 AMPLITUDE trial of inaxaplin, with interim results expected in early 2027.⁴

PARASOL Proteinuria Data Support Combination Therapy in FSGS

Weins said the PARASOL data reinforce the case for aggressive proteinuria control.

“We’ve learned a lot from the PARASOL data that just came out, that really any reduction in proteinuria is beneficial to those patients,” she said. “So we should do anything we can to reduce proteinuria.”

That points to multidrug regimens, with selection guided by disease activity and cause.

“A combination of drugs will likely be what we’re looking at,” Weins said. “But I think we can be more targeted specifically when we know what phase of disease we’re in and what cause is at play at the moment.”

Editor’s Note: Weins reports relevant disclosures with Vera Therapeutics, Sysmex, and Novartis.

References
  1. Weins A, Radhakrishnan J, Tesar V. Advances in treatment and management of FSGS. Presented at: American Society of Nephrology Kidney Week 2026; October 22, 2026; Denver, CO.
  2. Hillenbrand A. FDA approves sparsentan for focal segmental glomerulosclerosis. HCPLive. Published April 13, 2026. Accessed November 18, 2026. https://www.hcplive.com/view/fda-approves-sparsentan-for-focal-segmental-glomerulosclerosis
  3. Trachtman H, Kretzler M, Gesualdo L, et al. TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198. Lancet. 2026;407(10528):587-598. doi:10.1016/S0140-6736(25)02255-X
  4. Hillenbrand A. Inaxaplin cuts proteinuria in broader APOL1 kidney disease population. HCPLive. Published September 23, 2026. Accessed November 18, 2026. https://www.hcplive.com/view/inaxaplin-cuts-proteinuria-in-broader-apol1-kidney-disease-population

Advertisement
Advertisement